EADO
European Association of Dermato Oncology

Course Directors
Claus Garbe, Tuebingen, Germany
Axel Hauschild, Kiel, Germany
Veronique del Marmol, Brussels, Belgium
Giovanni Pellacani, Rome, Italy

12th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY – UPDATE ON CUTANEOUS ONCOLOGY (ESDO)

JANUARY 12th–13th, 2024

NOVOTEL BERLIN AM TIERGARTEN
BERLIN, GERMANY

FINAL PROGRAM

This activity is provided by EADO. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

LIBTAYO® (cemiplimab)

LIBTAYO® is the FIRST AND ONLY immunotherapy indicated in both advanced CSCC and advanced BCC.[1]

- LIBTAYO demonstrated clinically meaningful responses[1*†‡§ll]
- LIBTAYO demonstrated durable responses[1]
- LIBTAYO has been studied for >8 years across several clinical trials, with a generally consistent safety profile across approved indications[1-3]

For more information on adverse events, please refer to the full Prescribing Information.[1]

APPROVED
IN ADVANCED CSCC

APPROVED
IN ADVANCED BCC

Empowered decision-making for your patients with aCSCC or aBCC

LIBTAYO is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.[1]

LIBTAYO is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).[1]

Study 1540 was an open-label, multicentre study that enrolled 193 patients with mCSCC or laCSCC with a combined median follow-up of 15.7 months. Treatment continued until disease progression, unacceptable toxicity, or completion of planned treatment. The primary endpoint was confirmed ORR as assessed by ICR. Secondary endpoints included DOR, PFS, OS, and CR rate.[1]

Study 1620 was an open-label, multicentre, non-randomized study that included patients with aBCC who had progressed on HHI therapy, were intolerant of prior HHI therapy, or had no better than SD after 9 months on HHI therapy (exclusive of treatment breaks). Treatment continued until progression of disease, unacceptable toxicity, or completion of planned treatment. The primary endpoint was confirmed ORR as assessed by ICR. Secondary endpoints included CR rate and DOR.[1,2]

The recommended dose is 350 mg of LIBTAYO every 3 weeks (Q3W) administered as an intravenous infusion over 30 minutes. Treatment may be continued until disease progression or unacceptable toxicity.[1]

*Data cutoff is 1 March 2022 for Groups 1 to 3 (Study 1540). Data cutoff is 17 February 2020 (Study 1620).[2,4]; †In Study 1540, the median durations of follow-up for Groups 1, 2, and 3 were 18.5, 15.5, and 17.3 months, respectively.[1]; ‡In Study 1620, the median duration of follow-up was 15.9 months for patients with laBCC and 8.4 months for patients with mBCC.[1]; §Non-evaluable and non-CR/non-PD patients are not presented in BOR results.[1]; llPatients with laBCC in Study 1620 required biopsy to confirm CR.[1] Based on Kaplan-Meier estimates.[1]

aBCC=advanced BCC; **aCSCC**=advanced CSCC; **BCC**=basal cell carcinoma; **BOR**=best overall response; **CR**=complete response; **CSCC**=cutaneous squamous cell carcinoma; **DOR**=duration of response; **ICR**=independent central review; **NE**=nonevaluable; **ORR**=objective response rate; **OS**=overall survival; **PD**=progressive disease; **PFS**=progression-free survival; **PR**=partial response; **SD**=stable disease.

References: 1. LIBTAYO (cemiplimab) EU prescribing information. Juni 2023. **2.** Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncol*. 2021;22(6):848-857. **3.** Study of REGN2810 (anti-PD-1) in patients with advanced malignancies. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/study/NCT02383212. Updated 27 January 2020. Accessed 19 October 2023. **4.** Migden MR, Schmults CD, Khushalani NI, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Poster presented at: European Society of Medical Oncology (ESMO) 2022 Annual Meeting; 9-13 September 2022; Paris, France.

Libtayo® 350 mg Concentrate for solution for infusion
Active substance: cemiplimab. **Composition:** *Active pharmaceutical ingredient:* 350 mg cemiplimab/vial (corresponding to 50 mg/ml). Cemiplimab is produced by recombinant DNA technology in a cell suspension culture from Chinese Hamster Ovarian Cells (CHO). *Excipients:* histidine, histidine hydrochloride monohydrate, sucrose, proline, polysorbate 80, water for injection. **Therapeutic Indications:** Indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation therapy. Indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma who have experienced disease progression on a *hedgehog pathway inhibitor* (HHI) or who have an intolerance to HHI. Indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 (in ≥50% of tumour cells) and lacking EGFR, ALK, or ROS1-aberrations. Treatment is intended for: patients with locally advanced NSCLC who are not candidates for definitive radiochemotherapy or patients with metastatic NSCLC. Indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1 % of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC. Indicated as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. **Contraindications:** Hypersensitivity to the active pharmaceutical ingredient or one of the excipients. **Adverse reactions: Cemiplimab as monotherapy:** *Infections and infestations:* Very common: upper respiratory tract infection; Common: urinary tract infection. *Blood and lymphatic system disorders:* Very common: anaemia; Not known: haemophagocytic lymphohistiocytosis. *Immune system disorders:* Common: reaction in conjunction with an infusion; Uncommon: Thrombocytopaenia, Sjögren's syndrome; Not known: rejection of solid organ transplants. *Endocrine disorders:* Common: hypothyreosis, hyperthyroidism; uncommon: adrenal insufficiency, thyroiditis, hypophysitis; Rare: Type 1 diabetes mellitus. *Nervous system disorders:* Common: headache, peripheral neuropathy; Rare: meningitis, encephalitis, myasthenia gravis, paraneopl. encephalomyelitis, chronic inflammatory demyelinating polyradiculoneuropathy. *Eye disorders:* Uncommon: keratitis. *Cardiac disorders:* Uncommon: myocarditis, pericarditis; *Vascular disorders:* Common: hypertension *Metabolism and nutrition disorders:* Very common: decreased appetite. *Respiratory, thoracic and mediastinal disorders:* Very common: cough; Common: pneumonitis, dyspnoea. *Gastrointestinal disorders:* Very common: nausea, diarrhoea, constipation, abdominal pain; Common: vomiting, stomatitis, colitis; Uncommon: Gastritis; *Hepatobiliary disorders:* Common: hepatitis: *Skin and subcutaneous tissue disorders:* Very common: rash, pruritus; Common: Actinic keratosis. *Musculoskeletal and connective tissue disorders:* Very common: musculoskeletal pain; Uncommon: arthritis, muscular weakness, myositis, polymyalgia rheumatica. *Renal and urinary disorders:* Common: nephritis. Not known: non-infectious cystitis. *General disorders and administration site conditions:* Very common: fatigue; Common: fever, oedema. *Investigations:* Common: alanine and/or aspartate aminotransferase increased, alk. phosphatase and/or blood creatinine increased; Uncommon: thyrotropin and/or transaminases and/or bilirubin increased; Rare: thyrotropin decreased. **Adverse reactions: Cemiplimab in combination with platinum-based chemotherapy:** *Blood and lymphatic system disorders:* Very common: anaemia, neutropaenia, thrombocytopaenia. *Immune system disorders:* Uncommon: infusion-related reaction. *Endocrine disorders:* Common: hypothyroidism, hyperthyroidism; Uncommon: thyroiditis, type 1 diabetes mellitus. *Nervous system disorders:* Very common: peripheral neuropathy. *Metabolism and nutrition disorders:* Very common: decreased appetite, hyperglycaemia, hypoalbuminaemia. *Respiratory, thoracic and mediastinal disorders:* Very Internal common: dyspnoea; Common: pneumonitis. *Gastrointestinal disorders:* Very common: nausea, diarrhoea, constipation, vomiting; Common: colitis. *Psychiatric disorders:* Very common: insomnia. *Skin and subcutaneous tissue disorders:* Very common: rash, alopecia; Common: pruritus. *Musculoskeletal and connective tissue disorders:* Very common: musculoskeletal pain; Common: arthritis. *Renal and urinary disorders:* Common: nephritis. *General disorders and administration site conditions:* Very common: fatigue. *Investigations:* Very common: alanine and/or aspartate aminotransferase increased, weight decreased; Common: alk. phosphatase and/or blood creatinine increased, thyroid stimulated hormone and/or bilirubin increased, thyroid stimulating hormone decreased; Uncommon: gamma-glutamyltransferase increased. **Prescription-only medicine**

Marketing authorisation holder: Regeneron Ireland Designated Activity Company (DAC), One Warrington Place, Dublin 2, D02 HH27, Ireland.
Local representative: Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main. Version: June 2023
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are requested to report any suspected adverse reaction.

MAT-DE-2304465 V1.0 10/23

sanofi | REGENERON®

Content

european-school-of-dermato-oncology.org

European Association of Dermato-Oncology (EADO)

The EADO is a non-profit organization founded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org).
The EADO initiates for the twelfth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease.

Target Audience

This 2-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.

4. The indications and methods for genetic diagnosis and genetic counseling of skin cancer patients.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.
6. The value of imaging and biomarkers for the detection of metastases and disease staging.
7. Adjuvant treatment of skin cancer: radiotherapy, immunotherapy, chemotherapy.
8. New systemic treatments for stage IV melanoma: targeted agents and immuno-therapeutics.
9. New treatment options of advanced basal cell carcinoma.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma.
14. Clinical trials in skin cancer: an update.
15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.
The main part of the course consists of 6 interactive sessions. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.

We look forward to welcoming you in Berlin in January 2024!

Claus Garbe, MD
Axel Hauschild, MD
Veronique del Marmol, MD
Giovanni Pellacani, MD
Course Directors

Program Overview

A commercial exhibition will be held on all days close to the meeting rooms.





This activity is provided by EADO. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Program

Friday, January 12th, 2024

Non-Melanoma Skin Cancer Day

09:00-09:15	**Welcome and Course Introduction on the NMSC Day** Claus Garbe, Tuebingen, Germany
	PLENARY SESSION 1: Non melanoma skin cancer (NMSC) I *Chairpersons: Christoph Höller, Vienna, Austria* *Iris Zalaudek, Trieste, Italy*
09:20-09:40	LECTURE 1: **New EADO Guideline for cutaneous squamous cell carcinoma (CSCC)** *Christoph Höller, Vienna, Austria*
09:50-10:10	LECTURE 2: **New EADO Guideline for actinic keratoses (AK)** *Lidija Kandolf, Belgrade, Serbia*
10:20-10:40	LECTURE 3: **New EADO Guideline basal cell carcinoma (BCC**) *Iris Zalaudek, Trieste, Italy*
10:50-11:10	LECTURE 4: **Guideline update for other NMSC** *Celeste Lebbé, Paris, France*
11:20-11:45	Break
11:45-12:45	COURSE A: **Dermoscopy of pigmented and non-pigmented lesions** *Iris Zalaudek, Trieste, Italy*
12:45-13:45	COURSE B: **My most interesting non-melanoma cases: an interactive session** *Axel Hauschild, Kiel, Germany*
13:45-14:30	Break

14:30-15:30	COURSE C: **Cutaneous lymphomas: diagnosis & management** *Chalid Assaf, Krefeld, Germany*
15:30-15:50	Keynote Lecture I: **Burden of skin cancer in Europe** *Lieve Brochez, Ghent, Belgium*
	PLENARY SESSION 2: **Non-melanoma skin cancer (NMSC) II** *Chairpersons: Ana-Maria Forsea, Bucharest, Romania* *David Moreno Ramirez, Seville, Spain*
15:50-16:10	LECTURE 5: **Screening for Skin Cancer** *Ana-Maria Forsea, Bucharest, Romania*
16:20-16:40	LECTURE 6: **Surgical pearls in NMSC** *David Moreno Ramirez, Seville, Spain*
16:50-17:10	LECTURE 7: **The role of radiotherapy in NMSC** *Angela Besserer, Berlin, Germany*
17:20-17:40	LECTURE 8: **Nicotinamide for prevention of skin cancer** *Josep Malvehy, Barcelona, Spain*
17:50	**End of Day I**

Program

Saturday, January 13th, 2024

Melanoma Day

09:15-09:20	**Course Introduction Melanoma Day** *Giovanni Pellacani, Rome, Italy*
	PLENARY SESSION 3: **Melanoma I** *Chairpersons: Veronique del Marmol, Brussels, Belgium* *Giovanni Pellacani, Rome, Italy*
09:20-09:40	LECTURE 9: **Euromelanoma campaigns** *Veronique del Marmol, Brussels, Belgium*
09:50-10:10	LECTURE 10: **Melanoma diagnostics beyond dermoscopy** *Giovanni Pellacani, Rome, Italy*
10:20-10:40	LECTURE 11: **EADO Guideline for cutaneous melanoma** *Claus Garbe, Tuebingen, Germany*
10:50-11:10	LECTURE 12: **Intralesional treatment of skin cancer** *Axel Hauschild, Kiel, Germany*
11:20-11:45	Break
11:45-12:45	COURSE D: **Melanoma: how therapy changed and continues to develop** *Claus Garbe, Tuebingen, Germany*
12:45-13:45	COURSE E: **Practical aspects in the surgical management of melanomas** *Roland Kaufmann, Frankfurt, Germany*
13:45-14:30	Break

14:30-15:30	COURSE F: **Management of patients with distant metastatic melanoma (Stage IV)** *Christoffer Gebhardt, Hamburg, Germany*
15:30-15:50	Keynote Lecture II: **Treatment at the end of life** *Andrea Forschner, Tuebingen, Germany*
	PLENARY SESSION 4: **Melanoma II** *Chairpersons: Andrea Forschner, Tuebingen, Germany* *Jessica Hassel, Heidelberg, Germany*
15:50-16:10	LECTURE 13: **Adjuvant treatment of high-risk melanoma primaries** *Thomas Eigentler, Berlin, Germany*
16:20-16:40	LECTURE 14: **Neoadjuvant/perioperative treatment of melanoma** *Christoph Höller, Vienna, Austria*
16:50-17:10	LECTURE 15: **Tebentafusp for metastatic ocular melanoma** *Jessica Hassel, Heidelberg, Germany*
17:20	**End of Day II**

17:30	**EUROPEAN EXAMINATION DERMATO-ONCOLOGY 2024** Room: Kurland 1	Only for authorized exam candidates

Course Faculty

A

Chalid Assaf, MD
Professor of Dermatology
Chief Physician of the Clinic for
Dermatology and Venerology
Krefeld, Germany

B

Angela Besserer, MD
Senior physician at the Clinic for
Radiooncology and Radiotherapy
Campus Benjamin Franklin, Charité Berlin
Berlin, Germany
Email: andrea.besserer@charite.de

Lieve Brochez, MD
Professor of Dermatology
Department of Dermatology
University Hospital Ghent
Ghent, Belgium

D

Veronique del Marmol, MD
Department of Clinical Chemistry
Erasme Hospital – ULB
Brussels, Belgium
Email: v.marmol@drvdm.be

E

Thomas Eigentler, MD
Professor of Dermatological Oncology
Skin Cancer Center
Campus Charite Mitte, Charité Berlin
Berlin, Germany

F

Ana-Maria Forsea, MD
Professor of Dermatology
Department of Dermatology
Carol Davila University of Medicine
and Pharmacy Bucharest
Bucharest, Romania

Andrea Forschner, MD
Head of Melanoma Ambulance
Department of Dermatology
Eberhard Karls University
Tuebingen, Germany

G

Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Tuebingen, Germany

Christoffer Gebhardt, MD
Skin Cancer Center
University Hospital Hamburg-Eppendorf
Hamburg, Germany

H

Axel Hauschild, MD
Professor of Dermatology
Department of Dermatology
University of Kiel
Kiel, Germany

Jessica Hassel, MD
Professor of Dermatology
University Hospital of Heidelberg
Heidelberg, Germany

Christoph Hoeller, MD
Professor of Dermatology
Department of Dermatology
Medical University of Vienna
Vienna, Austria

K

Lidija Kandolf, MD
Professor of Dermatology
Department of Dermatology
Medical Faculty
Military Medical Academy
Belgrade, Serbia

Roland Kaufmann, MD
Department of Dermatology
Clinical Center J. W. Goethe University
Frankfurt am Main, Germany

L

Celeste Lebbé, MD
Professor of Dermatology
Department of Dermatology
Hôpital Saint-Louis
Paris, France

M

Josep Malvehy, MD
Director of the Melanoma Unit
Department of Dermatology
Hospital Clinic of Barcelona
Barcelona, Spain

David Moreno Ramirez, MD
Professor of Dermatology at the
Faculty of Medicine-University of Seville
Head of the Dermatology Service of
the Virgen Macarena University Hospital
Sevilla, Spain

P

Giovanni Pellacani, MD
Professor of Dermatology
Chairman of Dermatology Department
La Sapienza University
Rome, Italy

Z

Iris Zalaudek, MD
Head of Department of Dermatology
University of Trieste
Trieste, Italy

General Information

Cancellation Policy

Cancellations must be received in writing by December 23, 2023. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

CME credits

The 12th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY – UPDATE ON CUTANEOUS ONCOLOGY (ESDO), Novotel Berlin Am Tiergarten, Strasse des 17. Juni 106, 10623 Berlin, Germany, Germany 12/01/2024-13/01/2024 has been granted 11 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Course Organization

MEDCONCEPT

MedConcept Gesellschaft für medizinische Projekte mbH
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
E-Mail: info@medconcept.org
www.medconcept.org

Course Venue

Novotel Berlin Am Tiergarten
Straße des 17. Juni 106
10623 Berlin, Germany

Phone: +49 (0)30 600350
E-Mail: H3649-SB@accor.com

Exhibition Opening Hours

Friday, January 12: 08:00-18:00
Saturday, January 13: 08:00-18:00

Fees

Registration Fee of **380 Euro (incl. VAT)** covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch
- Certificate of attendance

A reduced registration fee of **190 Euro (incl. VAT)** will be availbale for attendees from Eastern European countries, Students and Nurses.

Language and Translation

The official language of the meeting will be English.
Simultaneous translation will not be provided.

Registration / Information Desk

The registration desk is situated at the ground floor next to the reception.

Sponsors

DIAMOND SPONSOR

sanofi | REGENERON®

BRONZE SPONSOR

Bristol Myers Squibb™

EXHIBITORS

MSD

Philogen
innovating targeting

Pierre Fabre

SUN PHARMA

Notes

Notes

EADO
European Association of Dermato Oncology

20TH EADO CONGRESS 2024

APRIL 4th–6th, 2024

PARIS, FRANCE
Versailles Palais des Congrès

SAVE THE DATE

eado2024.com

Save the Date

June 27th–28th, 2024

Munich, Germany
Hilton Hotel Munich Park

14th European Post-Chicago Melanoma/Skin Cancer Meeting

EADO
European Association of Dermato Oncology

Melanoma World Society
MWS

Congress Presidents
Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany

3.–5. APRIL 2025

11TH WORLD CONGRESS OF MELANOMA AND 21ST EADO CONGRESS

Megaron Athens International Conference Centre
Athens, Greece

SAVE THE DATE

EADO
European Association of Dermato Oncology

Melanoma World Society
MWS

worldmelanoma2025.com

Final Program

January 12th–13th, 2024

Layout: MediaService GmbH Druck und Kommunikation
Printed on 100% recycled paper